TRPM2-AS Promotes Bladder Cancer by Targeting miR-22-3p and Regulating GINS2 mRNA Expression

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106–119. doi:10.1016/j.eururo.2016.02.028
   PubMed Web of Science ®Google Scholar
• Babjuk M. Trends in bladder cancer incidence and mortality: success or disappointment? Eur Urol. 2017;71(1):109–110. doi:10.1016/j.eururo.2016.06.040
   PubMed Web of Science ®Google Scholar
• Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–166. doi:10.1016/j.canlet.2013.06.013
   PubMed Web of Science ®Google Scholar
• Trimarchi T, Bilal E, Ntziachristos P, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158(3):593–606. doi:10.1016/j.cell.2014.05.049
   PubMed Web of Science ®Google Scholar
• Cheng W, Zhang Z, Wang J. Long noncoding RNAs: new players in prostate cancer. Cancer Lett. 2013;339(1):8–14. doi:10.1016/j.canlet.2013.07.008
   PubMed Web of Science ®Google Scholar
• Zhong X, Lu M, Wan J, Zhou T, Qin B. Long noncoding RNA kcna3 inhibits the progression of colorectal carcinoma through down-regulating YAP1 expression. Biomed Pharmacother. 2018;107:382–389. doi:10.1016/j.biopha.2018.07.118
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang P, Zhu H, Li S, Chen X, Shi L. Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway. Biomed Pharmacother. 2017;96:1103–1108. doi:10.1016/j.biopha.2017.11.113
   PubMed Web of Science ®Google Scholar
• Orfanelli U, Wenke AK, Doglioni C, Russo V, Bosserhoff AK, Lavorgna G. Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell Res. 2008;18(11):1128–1140. doi:10.1038/cr.2008.296
   PubMed Web of Science ®Google Scholar
• Orfanelli U, Jachetti E, Chiacchiera F, et al. Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene. 2015;34(16):2094–2102. doi:10.1038/onc.2014.144
   PubMed Web of Science ®Google Scholar
• Huang B, Chang C, Wang BL, Li H. ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/HMGA1 axis. J Cell Biochem. 2019;120(10):16921–16933. doi:10.1002/jcb.28951
   PubMed Web of Science ®Google Scholar
• Pan L, Li Y, Jin L, Li J, Xu A. TRPM2-AS promotes cancer cell proliferation through control of TAF15. Int J Biochem Cell Biol. 2020;120:105683. doi:10.1016/j.biocel.2019.105683
   PubMed Web of Science ®Google Scholar
• Sun T, Song Y, Yu H, Luo X. Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis’s proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis. Cancer Biol Ther. 2019;20(6):760–773. doi:10.1080/15384047.2018.1564563
   PubMed Web of Science ®Google Scholar
• Ma LY, Xie XW, Ma L, et al. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Eur Rev Med Pharmacol Sci. 2017;21(11):2626–2634.
   PubMed Web of Science ®Google Scholar
• Xu C, Huang Q, Zhang C, et al. Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma. Ir J Med Sci. 2018;187(3):621–628. doi:10.1007/s11845-017-1692-y
   PubMed Web of Science ®Google Scholar
• Huang C, Qin Y, Liu H, et al. Downregulation of a novel long noncoding RNA TRPM2-AS promotes apoptosis in non-small cell lung cancer. Tumour Biol. 2017;39(2):1010428317691191. doi:10.1177/1010428317691191
   Google Scholar
• Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep. 2001;2(11):986–991. doi:10.1093/embo-reports/kve230
   PubMed Web of Science ®Google Scholar
• Ahadi A, Brennan S, Kennedy PJ, Hutvagner G, Tran N. Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes. Sci Rep. 2016;6:24922. doi:10.1038/srep24922
   PubMed Web of Science ®Google Scholar
• Seok H, Ham J, Jang ES, Chi SW. MicroRNA target recognition: insights from transcriptome-wide non-canonical interactions. Mol Cells. 2016;39(5):375–381.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhan F, Li D, Wang T, Huang H. RGMB-AS1/miR-22-3p/NFIB axis contributes to the progression of gastric cancer. Neoplasma. 2020;67:484–491. doi:10.4149/neo_2020_190418N350
   PubMed Web of Science ®Google Scholar
• Heidary Z, Zaki-Dizaji M, Saliminejad K, Edalatkhah H, Khorram Khorshid HR. MiR-4485-3p expression reduced in spermatozoa of men with idiopathic asthenozoospermia. Andrologia. 2020;52(3):e13539. doi:10.1111/and.13539
   PubMed Web of Science ®Google Scholar
• Liang L, Xu J, Wang M, et al. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge. Cell Death Dis. 2018;9(3):372. doi:10.1038/s41419-018-0382-7
   PubMedGoogle Scholar
• Qiu BQ, Zhang PF, Xiong D, et al. CircRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling. J Cell Physiol. 2019;234(7):11256–11264. doi:10.1002/jcp.27783
   PubMed Web of Science ®Google Scholar
• Sha QK, Chen L, Xi JZ, Song H. Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1057–1066. doi:10.1080/21691401.2018.1544143
   PubMed Web of Science ®Google Scholar
• Jiang W, Han X, Wang J, et al. miR-22 enhances the radiosensitivity of small-cell lung cancer by targeting the WRNIP1. J Cell Biochem. 2019;120(10):17650–17661. doi:10.1002/jcb.29032
   PubMed Web of Science ®Google Scholar
• Chen J, Wu FX, Luo HL, et al. Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1. Am J Transl Res. 2016;8(11):4932–4941.
   PubMed Web of Science ®Google Scholar
• MacNeill SA. Structure and function of the GINS complex, a key component of the eukaryotic replisome. Biochem J. 2010;425(3):489–500. doi:10.1042/BJ20091531
   PubMedGoogle Scholar
• Labib K, Gambus A. A key role for the GINS complex at DNA replication forks. Trends Cell Biol. 2007;17(6):271–278. doi:10.1016/j.tcb.2007.04.002
   PubMed Web of Science ®Google Scholar
• Kamada K. The GINS complex: structure and function. Subcell Biochem. 2012;62:135–156.
   PubMedGoogle Scholar
• Huang J, Li Y, Lu Z, et al. Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report. Cell Oncol (Dordr). 2019;42(4):571–578. doi:10.1007/s13402-019-00438-y
   PubMed Web of Science ®Google Scholar
• Ye Y, Song YN, He SF, Zhuang JH, Wang GY, Xia W. GINS2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating CITED2 and LOXL2. Cancer Gene Ther. 2019;26(3–4):103–113. doi:10.1038/s41417-018-0045-y
   PubMed Web of Science ®Google Scholar
• Liu X, Sun L, Zhang S, Zhang S, Li W. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. J Cell Physiol. 2019.
   Google Scholar
• Rantala JK, Edgren H, Lehtinen L, et al. Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia. 2010;12(11):877–888. doi:10.1593/neo.10548
   PubMed Web of Science ®Google Scholar
• Peng L, Song Z, Chen D, et al. GINS2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative breast cancer. Biomed Pharmacother. 2016;84:1568–1574. doi:10.1016/j.biopha.2016.10.032
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhou Y, Yang X, et al. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res Treat. 2014;148(2):423–436. doi:10.1007/s10549-014-3172-7
   PubMed Web of Science ®Google Scholar
• Ouyang F, Liu J, Xia M, et al. GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol Rep. 2017;37(5):2652–2662. doi:10.3892/or.2017.5573
   PubMed Web of Science ®Google Scholar
• Yan T, Liang W, Jiang E, Ye A, Wu Q, Xi M. GINS2 regulates cell proliferation and apoptosis in human epithelial ovarian cancer. Oncol Lett. 2018;16(2):2591–2598. doi:10.3892/ol.2018.8944
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong L, Liu BZ, Gao YJ, Gao YM, Hu XX. Effect of GINS2 on proliferation and apoptosis in leukemic cell line. Int J Med Sci. 2013;10(12):1795–1804. doi:10.7150/ijms.7025
   PubMedGoogle Scholar
• Kacich RL, Williams LT, Coughlin SR. Arachidonic acid and cyclic adenosine monophosphate stimulation of c-fos expression by a pathway independent of phorbol ester-sensitive protein kinase C. Mol Endocrinol. 1988;2(1):73–77. doi:10.1210/mend-2-1-73
   PubMedGoogle Scholar
• Xu M, Li J, Wang X, et al. MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop. Cell Death Dis. 2018;9(2):209. doi:10.1038/s41419-017-0206-1
   PubMed Web of Science ®Google Scholar
• Zeng Q, Liu J, Cao P, et al. Inhibition of REDD1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy. Clin Cancer Res. 2018;24(2):445–459. doi:10.1158/1078-0432.CCR-17-0419
   PubMed Web of Science ®Google Scholar
• He W, Zhang Y, Xia S. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis. Thorac Cancer. 2020;11:549–560. doi:10.1111/1759-7714.13280
   PubMed Web of Science ®Google Scholar
• Zong W, Feng W, Jiang Y, et al. LncRNA CTC-497E21.4 promotes the progression of gastric cancer via modulating miR-22/NET1 axis through RhoA signaling pathway. Gastric Cancer. 2020;23(2):228–240. doi:10.1007/s10120-019-00998-w
   PubMed Web of Science ®Google Scholar